Dr. Andreas K. Klein
Claim this profileTufts Medical Center
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Cancer
13 reported clinical trials
31 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
CD19 positive
13q positive
13q negative
2Cancer
CD19 positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Andreas K. Klein is currently running
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting1 award Phase 217 criteria
More about Andreas K. Klein
Clinical Trial Related6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Andreas K. Klein has experience with
- Venetoclax
- Azacitidine
- Cyclophosphamide
- Cytarabine
- Daunorubicin Hydrochloride
- Obinutuzumab
Breakdown of trials Andreas K. Klein has run
T-Lymphoblastic Leukemia/Lymphoma
Cancer
Acute Myeloid Leukemia
Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andreas K. Klein specialize in?
Andreas K. Klein focuses on T-Lymphoblastic Leukemia/Lymphoma and Cancer. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved CD19 positive patients, or patients who are 13q positive.
Is Andreas K. Klein currently recruiting for clinical trials?
Yes, Andreas K. Klein is currently recruiting for 9 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Andreas K. Klein has studied deeply?
Yes, Andreas K. Klein has studied treatments such as Venetoclax, Azacitidine, Cyclophosphamide.
What is the best way to schedule an appointment with Andreas K. Klein?
Apply for one of the trials that Andreas K. Klein is conducting.
What is the office address of Andreas K. Klein?
The office of Andreas K. Klein is located at: Tufts Medical Center, Boston, Massachusetts 02111 United States. This is the address for their practice at the Tufts Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.